Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Merck & Co., Inc.    MRK

Delayed Quote. Delayed  - 08/30 04:50:56 pm
62.97 USD   -0.06%
08/25 INSIDE THE FDA : Frontrunners Merck & Co., Inc. (NYSE:MRK), GlaxoSm..
08/23DJDeal for Medivation Is the Latest In a Line of Similar Acquisitio..
08/22DJPfizer's Medivation Deal Latest in Long Line of Similar Acquisiti..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

US Judge Upholds Validity Of Merck's Vytorin Patent

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/28/2012 | 12:29am CEST

--Judge rules U.S. patent for Vytorin and Zetia is valid and enforceable

--Mylan had challenged patent in bid to sell generic Vytorin and Zetia

--Merck patent due to expire in April 2017

(Adds statement from Merck, additional details.)

 
   By Peter Loftus 
   Of  
 

A federal judge has upheld the validity of a U.S. patent covering Merck & Co.'s (>> Merck & Co., Inc.) cholesterol-lowering drugs Vytorin and Zetia, which could stave off competing generic copies for several years.

In an opinion released Friday, U.S. District Judge Jose Linares in federal court in Newark, N.J., said the patent for was valid and enforceable. The patent covers ezetimibe, an active ingredient in both Zetia and Vytorin.

Merck, based in Whitehouse Station, N.J., said the U.S. patent for Vytorin and Zetia is due to expire in April 2017.

"The court appropriately ruled that the patent for Zetia and Vytorin in the U.S. is valid and enforceable," Bruce N. Kuhlik, executive vice president and general counsel of Merck, said in a press release.

Mylan Inc. (MYL) had applied for U.S. Food and Drug Administration approval to sell generic versions of Vytorin and Zetia before the patent expired, arguing that the patent was invalid and unenforceable.

Merck filed a patent-infringement lawsuit against Mylan in late 2009, seeking to block Mylan's plan to sell generic Vytorin, and in 2010 sued to block Mylan from selling generic Zetia. A trial was held in December 2011, leading to Judge Linares's opinion Friday.

Merck said the court also issued an injunction blocking the approval of Mylan's generic versions until the expiration of the patent.

A Mylan spokeswoman couldn't immediately be reached for comment.

Earlier Friday, Merck reported first-quarter Vytorin sales of $444 million and Zetia sales of $614 million.

Merck previously reached a settlement of patent litigation for Zetia with generics manufacturer Glenmark Pharmaceuticals. The pact will allow Glenmark to sell generic Zetia in December 2016, subject to final regulatory approval.

-By Peter Loftus, Dow Jones Newswires; 215-982-5581; peter.loftus@dowjones.com

Stocks mentioned in the article : Merck & Co., Inc.
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MERCK & CO., INC.
08/25 INSIDE THE FDA EBOLA EDITION : Frontrunners Merck & Co., Inc. (NYSE:MRK), GlaxoS..
08/23DJDeal for Medivation Is the Latest In a Line of Similar Acquisitions -- WSJ
08/22DJPfizer's Medivation Deal Latest in Long Line of Similar Acquisitions
08/17 DOW MOVERS : Csco, pfe
08/17 INVESTORSOBSERVER : releases covered-call reports for NVIDIA, Dicks Sporting Goo..
08/11 MERCK : Findings from Merck & Company in the Area of Medicinal Chemistry Reporte..
08/10 MERCK : Amica Mutual Insurance Co Lowers stake in Merck & Co. (MRK)
08/09DJMARKET SNAPSHOT : Stocks March Higher, Buoyed By Health-care, Consumer-staples G..
08/09 DOW MOVERS : Mrk, gs
08/09DJBotox Maker Allergan's Revenue Climbs, but Loss More Than Doubles -- WSJ
More news
Sector news : Pharmaceuticals - NEC
04:01pDJOrexigen in Canadian Marketing Pact With Valeant for Diet Drug
08:49aDJBusiness Watch -- WSJ
08/29 Mylan to launch generic EpiPen at half the price of original
08/29DJMondelez Walks Away After Hershey Spurns Raised Bid
08/29DJROCHE : Receives US FDA Emergency Use Authorization for Zika Test -- Update
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
09:31a Is Gilead Sciences A Bargain?
08/29 S&P 500 Dogs Get Technical As Brokers See WDC For Upside & FTR For Gains In A..
08/29 Amgen announces new data supporting Repatha's efficacy
08/27 The EpiPen Lies
08/27 Using My SWAN Decision Tree To Rate DGI Stocks
Advertisement
Financials ($)
Sales 2016 39 681 M
EBIT 2016 13 578 M
Net income 2016 5 853 M
Debt 2016 4 707 M
Yield 2016 2,94%
P/E ratio 2016 30,59
P/E ratio 2017 20,83
EV / Sales 2016 4,51x
EV / Sales 2017 4,45x
Capitalization 174 236 M
More Financials
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders
Full-screen chart
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 65,5 $
Spread / Average Target 3,9%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis Chief Financial Officer & Executive Vice President
Michael A. Rosenblatt Chief Medical Officer & Executive Vice President
Clark Golestani Chief Information Officer & Executive VP
Thomas Henry Glocer Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MERCK & CO., INC.19.29%174 236
JOHNSON & JOHNSON16.74%328 086
PFIZER INC.8.77%212 965
ROCHE HOLDING LTD.-12.84%212 954
NOVARTIS AG-10.83%208 887
ASTRAZENECA PLC7.33%173 471
More Results